Salvage therapy with topotecan in heavily pretreated ovarian cancer patients

Journal of Cancer Research and Clinical Oncology

Volumn 135, Issue 6, 2009, Pages 815-821

  Bodnar, Lubomir ^a   Wcislo, Gabriel ^a   Nasilowska, Anna ^a   Szarlej Wcislo, Katarzyna ^a   Gasowska Bodnar, Agnieszka ^a   Smoter, Marta ^a   Szczylik, Cezary ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

Author keywords

Recurrent ovarian cancer; Salvage chemotherapy; Topotecan

Indexed keywords

CA 125 ANTIGEN; DOXORUBICIN; PACLITAXEL; PLATINUM; TOPOTECAN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; CYTOREDUCTIVE SURGERY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INFUSION; FEASIBILITY STUDY; FEMALE; HUMAN; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SALVAGE THERAPY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ALOPECIA; ANEMIA; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NAUSEA; NEUTROPENIA; OVARIAN NEOPLASMS; SALVAGE THERAPY; SURVIVAL ANALYSIS; TOPOTECAN; TREATMENT OUTCOME; VOMITING;

EID: 67349195307     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-008-0517-9     Document Type: Article

References (23)

1. DK Armstrong D Spriggs J Levin R Poulin S Lane 2005 Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis Oncologist 10 686 694 10.1634/theoncologist.10-9- 686
2. MA Bookman H Malmstrom G Bolis 1998 Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel J Clin Oncol 16 3345 3352
3. Common Terminology Criteria for Adverse Events, Version 3.0, revised 10 June 2003. National Cancer Institute, http://ctep.cancer.gov/forms/CTCAEv3.pdf
4. GJ Creemers B Lund J Verweij 1994 Topoisomerase I inhibitors: topotecan and irinotecan Cancer Treat Rev 20 73 96 10.1016/0305-7372(94)90011-6
5. GJ Creemers G Bolis M Gore 1996 Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study J Clin Oncol 14 3056 3061
6. AA Garcia 1999 Salvage therapy for ovarian cancer Curr Oncol Rep 1 64 70 10.1007/s11912-999-0012-8
7. AN Gordon JT Fleagle D Guthrie DE Parkin ME Gore AJ Lacave 2001 Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J Clin Oncol 19 3312 3322
8. AN Gordon M Tonda S Sun W Rackoff 2004 Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in phase 3 randomized study of recurrent and refractory epithelial ovarian cancer Gynecol Oncol 95 1 8 10.1016/j.ygyno.2004.07.011
9. A Jemal T Murray A Samuels A Ghafoor E Word M Thun 2003 Cancer statistics, 2003 CA Cancer J Clin 53 5 26
10. T Lynch 1996 Topotecan today J Clin Oncol 14 3053 3055
11. WP McGuire JA Blessing MA Bookman 2000 Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group study J Clin Oncol 18 1062 1067
12. JP Neijt WW ten Bokkel Huinink ME van der Burg AT van Oosterom PH Willemse JB Vermorken AC van Lindert AP Heintz E Aartsen M van Lent 1991 Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer Eur J Cancer 27 1367 1372
13. HA Nielsen D Nielsen SA Engelholm 2000 Effect of topotecan on serum Ca-125 in patients with advanced epithelial ovarian cancer Gynecol Oncol 77 383 388 10.1006/gyno.2000.5760
14. RF Ozols 2002 Update on the management of ovarian cancer Cancer J 8 Suppl 1 15 21
15. B Piura A Rabinovich 2005 Topotecan in heavily pretreated patients with recurrent ovarian, peritoneal, and fallopian tube carcinoma Int J Gynecol Cancer 15 612 617 10.1111/j.1525-1438.2005.00116.x
16. RP Rocconi AS Case JM Straughn Jr JM Estes EE Partridge 2006 Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: a cost-effectiveness analysis Cancer 107 536 543 10.1002/cncr.22045
17. GJ Rustin AE Nelstrop SM Bentzch SJ Bond P McClean 2000 Selection of active drugs for ovarian cancer based on CA 125 and standard response rates in phase II trials J Clin Oncol 18 1733 1739
18. T Safra J Menczer R Bernstein S Shpigel MJ Inbar D Grisaru A Golan T Levy 2007 Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer Gynecol Oncol 105 205 210 10.1016/j.ygyno.2006.11. 017
19. WA Spannuth CA Leath WK Huh MN Barnes SA Davidson LC Kilgore EE Partridge JM Austin RD Alvarez 2007 A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy Gynecol Oncol 104 591 595 10.1016/j.ygyno.2006.09.008
20. EM Swisher DG Mutch JS Rader 1997 Topotecan in platinum- and paclitaxel-resistant ovarian cancer Gynecol Oncol 66 480 486 10.1006/gyno.1997.4787
21. S Tangjitgamol HT See S Manusirivithaya CF Levenback DM Gershenson JJ Kavanagh 2004 Third-line chemotherapy in platinum- and paclitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients Int J Gynecol Cancer 14 804 814 10.1111/j.1048-891X.2004.014512.x
22. W ten Bokkel Huinink M Gore J Carmichael 1997 Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer J Clin Oncol 15 2183 2193
23. P Therasse SG Arbuck E Eisenhauer 2000 New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 205 216 10.1093/jnci/92.3.205